FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet The U.S. Food and Drug Administration warns consumers to use extreme care when purchasing any products over the Internet that claim to diagnose, prevent, treat or cure the H1N1 influenza virus. The warning comes after the FDA recently purchased and analyzed several products represented online as Tamiflu (oseltamivir), which may pose risks to patients.
Read more...
http://www.worldpharmanews.com/content/view/981/1/
FDA Approves CRESTOR for Use in Pediatric Patients with Heterozygous Familial Hypercholesterolemia AstraZeneca announced the US Food and Drug Administration (FDA) approved CRESTOR (rosuvastatin calcium) for use in children ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.
Read more...
http://www.worldpharmanews.com/content/view/980/1/
Pfizer And Wyeth Become One: Working Together For A Healthier World™ Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.
Read more...
http://www.worldpharmanews.com/content/view/979/1/
Med-e-Tel 2010 - The International eHealth, Telemedicine and Health ICT Forum 14-16 April 2010, Luxembourg.
eHealth, Telemedicine and Health ICT are a tool at the service of medical and nurse practitioners, patients, citizens, healthcare institutions and governments. It involves many different stakeholders who need to be brought face-to-face to share aspirations, learn from research and experiences, show the possibilities, understand the market, discover new applications.
Read more...
http://www.worldpharmanews.com/content/view/978/1/
Pfizer Completes Acquisition Of Wyeth Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders.
Read more...
http://www.worldpharmanews.com/content/view/977/1/
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy GlaxoSmithKline (GSK) and Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, have entered into an exclusive worldwide collaboration for the development and commercialisation of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD).
Read more...
http://www.worldpharmanews.com/content/view/976/1/
Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau Pfizer Inc (NYSE:PFE) has announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer's pending acquisition of Wyeth. In addition, Pfizer has received approval from the Canadian Competition Bureau for the pending acquisition.
Read more...
http://www.worldpharmanews.com/content/view/975/1/
Expert Panel Offers Three-Step Plan to Guide People Toward Recovery of Depression A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well.(1)
Read more...
http://www.worldpharmanews.com/content/view/974/1/
Abbott Reports 16.5 Percent Earnings Growth in Third Quarter Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009. "Abbott is performing well, generating higher-than-expected earnings growth in the third quarter," said Miles D. White, chairman and chief executive officer, Abbott.
Read more...
http://www.worldpharmanews.com/content/view/973/1/
Cleveland Clinic Top 10 Medical Innovations for 2010 The purpose of Cleveland Clinic's annual "Top 10 Medical Innovations" is to share the perspective on what innovations would help to re-shape health care in the next year. Top 10 are representing the final results of a rigorous selection process when clinicians and researchers at the Cleveland Clinic have been asked: "What game-changing medical technology, device, or therapy do you see breaking through in 2010?"
Read more...
http://www.worldpharmanews.com/content/view/972/1/
PharmaNews.eu / Latest News
With best regards,
Ruslan David, MD
Administrator/Editor